We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vibe Growth Corporation | CSE:VIBE | CSE | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.21 | 0.105 | 0.185 | 257 | 00:00:00 |
2019 Operational Highlights(a)
For the full year ended December 31, 2019 Vibe generated positive Adjusted EBITDA of $293,224. Management anticipates positive EBITDA during the first quarter of 2020 and for fiscal year 2020 as a result of expanded operations, prudent fiscal management initiatives implemented in 2019 and continuing process improvements:
Financial Update:
The Company’s core cannabis business did not commence until the acquisition of the U.S. Targets on February 18, 2019. Consequently, revenue, gross margin, G&A, selling and marketing expense and adjusted EBITDA amounts include results of; (i) the U.S. Targets from February 18, 2019 to December 31, 2019; and (ii) the Company’s head office for the entire twelve months ended December 31, 2019. In 2018, the Company’s activities consisted of identifying and evaluating cannabis cultivation, retail dispensary and other ancillary business opportunities with a view to negotiate and enter into letters of intent and definitive agreements with respect to acquiring or developing such assets. The Company’s key financial results for the three and twelve months ended December 31, 2019 are as follows:
U.S. dollars | Three Month EndedDecember 31, 2019 | The Year Ended December 31, 2019 | |
Total revenue(a) | $4,012,850 | $12,600,159 | |
Gross margin | $1,178,152 | $4,617,645 | |
Gross margin %(a) | 29.4 | 36.6 | |
Adjusted EBITDA(a) | $(158,313) | $293,224 | |
Adjusted EBITDA %(a) | (3.9) | 2.3 |
(a) This is a non-IFRS measure. Readers are cautioned that the amounts presented do not have standardized meanings prescribed by IFRS
Catalysts for 2020:
Vibe anticipates further growth over the next 12 months and positive EBITDA in the first quarter of 2020 and fiscal 2020 as a result of the 2019 operations highlights outlined above in addition to the following catalysts:
Outlook:
In the fourth quarter of 2019, the Company continued to build on the positive results realized in the first five and a half months of operating two dispensaries and a cultivation facility. The U.S. Targets also benefited from positive seasonal effects in both the second and third quarters of 2019, whereas the fourth and first quarters are slower months for the Company. Vibe’s Sacramento location launched its door-to-door delivery service in June 2019 and improvements to the store layout continue in connection with the first phase of the upgrades and improvements being made to the Sacramento Cannabis Campus. Vibe’s delivery service and online ordering system have been critical in meeting growing customer demand brought on by the COVID-19 pandemic.
Management expects the profitability of the U.S. Targets will continue in 2020 with the introduction of the new Hype Cannabis Co. Extracts line of products launched in August 2019, opening the Redding dispensary, additional cultivation capacity, continued roll-out of the door-to-door delivery service and ongoing improvements being made to existing dispensaries. Management expects the gross margin(a) realized by the dispensaries to be in the 35 to 40 percent range in 2020. Management also anticipates Sacramento Cultivation will operate at a slight loss on a gross margin(a)basis for the remainder of the first quarter of 2020 and then to be a net contributor to the gross margin in 2020.
In addition, management expects the improvements and expansions completed at Sacramento Cultivation will increase wholesale revenue in addition to increasing sales of the Company’s proprietary “Hype Cannabis Co.” brand, while lowering product costs at its three dispensaries as a result of increased vertical integration(b). However, the full benefit of the investment in Sacramento Cultivation is not expected to be realized until 2020 or 2021, given the expected timeline to complete the upgrades.
The Company was partially negatively affected by increased general and administrative expenses incurred by the head office in the three months ended September 30, 2019 and December 31, 2019, largely due to a one-time charge of approximately $200,000 in the restructuring of the Canadian head office, investor relations service, insurance costs and other expenses associated with public company requirements subsequent to the Company’s public listing in April 2019. Management expects head office general and administrative expenses to be lower in 2020(b).
About Vibe Bioscience Ltd.
Vibe is a vertically integrated cannabis company delivering exceptional retail experiences with its Vibe by California brand and ethos, premier cultivation product and high-efficiency delivery and on-line sales. The Company’s management team brings expertise in retail, cannabis cultivation and mergers and acquisitions to support its U.S. expansion through accretive acquisitions and organic growth. For more information, please visit www.vibebycalifornia.com.
(a) This is a non-GAAP measure. Readers are cautioned that the amounts presented do not have standardized meanings prescribed by IFRS. See discussion of non-IFRS Measures in the MD&A for reconciliation to measures reported in the Company’s financial statements.
(b) This is a forward-looking statement. See “Forward-Looking Information”.
Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “anticipate”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events, and may be impacted as a result of general economic conditions or the ongoing COVID-19 pandemic. Actual future results may differ materially.
The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein. Risk factors related to the Company are described in the Company’s Listing Statement dated March 25, 2019, a copy of which is available under the Company’s profile on SEDAR.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any State securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable State securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.
Unlike in Canada which has Federal legislation uniformly governing the cultivation, distribution, sale and possession of medical cannabis under the Cannabis Act (Federal), readers are cautioned that in the U.S., cannabis is largely regulated at the State level. To the knowledge of Vibe Bioscience Ltd., there are to date a total of 33 states, plus the District of Columbia, that have legalized cannabis in some form. Notwithstanding the permissive regulatory environment of medical cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. Federal law. Strict compliance with State laws with respect to cannabis will neither absolve Vibe Bioscience Ltd. of liability under the U.S. Federal law, nor will it provide a defense to any Federal proceeding, which may be brought against Vibe Bioscience Ltd. Any such proceedings brought against Vibe Bioscience Ltd. may adversely affect its operations and financial performance.
Contact Information | |
Company Contact: | |
Mark Waldron, CEO | |
Phone: +1 833-420-VIBE | |
Email: info@vibebycalifornia.com | |
Website: www.vibebycalifornia.com | |
Investor Relations Contact: | |
Glen Nelson | |
Phone: +1 833-420-VIBE x 107 | |
Email: ir@vibebycalifornia.com |
1 Year Vibe Growth Chart |
1 Month Vibe Growth Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions